MYCOF (Noveris Health Sciences) Beta: -10.5703 (As of Jun. 25, 2026)


MYCOF Noveris Health Sciences Inc MYCOF
23 GF Score
Price $2.00
GF Value $0.52
Valuation Significantly Overvalued
View Full Analysis

What is Noveris Health Sciences Beta?

Noveris Health Sciences MYCOF 23 Beta is -10.5703 as of Jun. 25, 2026. GuruFocus rates MYCOF with a GF Score™ of 23/100 and a GF Value™ of $0.52 (Significantly Overvalued).

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Noveris Health Sciences's Beta is -10.5703.


Noveris Health Sciences  (OTCPK:MYCOF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Noveris Health Sciences Beta Related Terms


Noveris Health Sciences Beta Historical Data

* Premium members only.

The historical data trend for Noveris Health Sciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noveris Health Sciences Beta Chart

Noveris Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.58 3.67 1.05 0.83 3.01

Noveris Health Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.52 2.44 3.01 -15.61

MYCOF vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noveris Health Sciences Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Beta distribution charts can be found below:

* The bar in red indicates where Noveris Health Sciences's Beta falls into.


MYCOF
23GF Score
Noveris Health Sciences Inc MYCOF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noveris Health Sciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -10.5703 mean?
Noveris Health Sciences (MYCOF) has a Beta of -10.5703 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Noveris Health Sciences and its competitors.
Is Noveris Health Sciences' Beta too high?
Noveris Health Sciences' current Beta is -10.5703. Overall, Noveris Health Sciences has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Beta compare to ZTS?
Noveris Health Sciences' Beta of -10.5703 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Noveris Health Sciences and its competitors. Noveris Health Sciences's current Beta is -10.5703. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $2.00 — trading 284.6% above its estimated fair value. The current Beta is -10.5703. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Beta is -10.5703 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noveris Health Sciences (MYCOF) Overvalued in 2026?

Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued. The current stock price of $2.00 is trading 284.6% above its estimated GF Value™ of $0.52. GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.

Key valuation signals for MYCOF:

  • Beta: -10.5703
  • GF Value™: $0.52 vs. price of $2.00 (284.6% above fair value)
  • GF Score™: 23/100

No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Noveris Health Sciences Business Description

Other Exchanges 0NF1:GermanyNVRS:Canada
Address 1890 - 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score

Get the complete analysis for MYCOF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$0.52
GF Value